«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:

35

期数:

2018年5

页码:

415-417

栏目:

临床研究

出版日期:

2018-05-05

文章信息/Info

Title:

Effect of spleen ammonia peptide for wheezing children caused by correction virus

作者:

侯元婕

（惠州市中医医院儿科，广东　惠州　516001）

Author(s):

HOU Yuan-jie

（Department of Pediatrics，Huizhou Hospital of Traditional Chinese Medicine，Huizhou 516001，Guangdong Province，China）

关键词:

婴幼儿喘息; 病毒; 脾氨肽; T淋巴细胞亚群

Keywords:

infant wheezing; virus; spleen ammonia peptide; T lymphocyte subsets

分类号:

R725.6

DOI:

10.7683/xxyxyxb.2018.05.015

文献标志码:

A

摘要:

目的　探讨脾氨肽治疗婴幼儿病毒相关性喘息的临床效果。方法　将惠州市中医医院2015年5月至2016年2月收治的40例首次喘息发作的病毒相关性喘息患儿分为观察组和对照组，每组20例；2组患儿入院后均给予常规对症支持治疗，患儿喘息控制后观察组给予脾氨肽2 mg，口服，每日1次，疗程30 d；对照组仅在喘息复发时对症支持治疗。2组患儿治疗后6个月随访1次，记录2组患儿喘息发作和呼吸道感染情况，并于治疗前及治疗后6个月检测T淋巴细胞亚群水平。结果　治疗后6个月内，观察组患儿呼吸道感染次数、喘息发作次数、发作后治疗时间均低于对照组（t=4.835、2.847、2.355，P<0.05）；对照组和观察组患儿喘息复发率分别为85.00%（17/20）和25.00%（5/20），观察组患儿喘息复发率低于对照组（χ²=9.136，P<0.01）。对照组患儿治疗前与治疗后6个月血清CD3⁺、CD4⁺、CD8⁺水平和CD4⁺/CD8⁺比值比较差异均无统计学意义（t=2.101、1.735、1.971，P>0.05）；观察组患儿治疗后6个月血清CD3⁺、CD4⁺水平和CD4⁺/CD8⁺比值较治疗前显著升高（t=5.689、7.321、3.045，P<0.05），CD8⁺水平较治疗前显著下降（t=6.523，P<0.05） 。治疗后6个月，观察组患儿血清CD3⁺、CD4⁺水平和CD4⁺/CD8⁺比值显著高于对照组（t=4.269、5.219、4.107，P<0.05），但2组患儿血清CD8⁺水平比较差异无统计学意义（t=1.678，P>0.05）。结论　脾氨肽可能通过提高病毒相关性喘息患儿的细胞免疫水平而减少其喘息发作频率和呼吸道感染频率。

Abstract:

Objective　To investigate the effect of spleen ammonia peptide for asthma children caused by correction virus.Methods　Forty children with wheezing for the first time in Huizhou Hospital of Traditional Chinese Medicine from May 2015 to February 2016 were selected and divided into control group and observation group，with 20 cases in each group.After admitted to hospital，all the patients were given conventional treatment of symptomatic support.The patients in the observation group were given spleen ammonia peptide orally 2 mg per time，once a day for 30 days;while the patients in the control group were only given symptomatic treatment after the wheezing relapsed.All the patients were followed up after six months，the frequency of wheezing and the respiratory tract infection of the two groups were recorded，and the level of T lymphocyte subsets was monitored before and 6 months after treatment.Results　Within six months after treatment，the frequency of respiratory tract infection and wheezing relapse，time of therapy for wheezing in the the observation group were lower than those in the control group （t=4.835,2.847,2.355;P<0.05）.The recurrence rate of wheezing in the control group and observation group was 85.00%（17/20） and 25.00%（5/20），The recurrence rate of wheezing in the observation group was lower than that in the control group（χ²=9.136，P<0.01）.There was no significant difference in the level of serum CD3⁺，CD4⁺，CD8⁺ and CD4⁺/CD8⁺ in the control group before and after treatment（t=2.101,1.735,1.971;P>0.05）.The level of serum CD3⁺，CD4⁺ and CD4⁺/CD8⁺ after treated for six months in the observation group was higher than that before treatment（t=5.689，7.321，3.045；P<0.05），and the level of serum CD8⁺ was lower（t=6.523,P<0.05）.Compared with the control group，the level of serum CD3⁺，CD4⁺ and CD4⁺/CD8⁺ after treated for six months in the observation group was higher（t=4.269，5.219，4.107；P<0.05），but there was no significant difference in the level of serum CD8⁺ （t=1.678,P>0.05）.Conclusion　The spleen ammonia peptide can effectively reduce the frequency of respiratory tract infection and wheezing relapse by enhancing the cell-mediated immunity level of wheezing children patients caused by correction virus.

常用功能

更新日期/Last Update: 2018-05-05